SCHEMBL15613670

SCHEMBL15613670

Cc1ncc(COc2cc(F)cc(Oc3ccc(-c4nn(CCN5CCOCC5)c5ncnc(N)c45)cc3)c2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 7/20 0.49
▸ YES1 P07947 5/20 0.49
▸ FGR P09769 5/20 0.49
▸ FYN P06241 5/20 0.46
▸ LYN P07948 3/20 0.46
▸ ABL1 P00519 3/20 0.45
▸ LCK P06239 2/20 0.45
▸ FRK P42685 2/20 0.45
▸ RET P07949 1/20 0.45
▸ PIK3CD O00329 1/20 0.44
▸ PIK3CA P42336 1/20 0.44
▸ PIK3CB P42338 1/20 0.44
▸ BTK Q06187 5/20 0.43
▸ EGFR P00533 1/20 0.43
▸ FGFR2 P21802 4/20 0.42
▸ FGFR1 P11362 3/20 0.42
▸ FGFR3 P22607 3/20 0.42
▸ FGFR4 P22455 2/20 0.42
▸ HCK P08631 1/20 0.41
▸ BLK P51451 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613649 0.96 SRC (0.45) SRCYES1FGRFYNLYN
SCHEMBL15613665 0.95 SRC (0.49) SRCYES1FGRFYNLYN
SCHEMBL16886171 0.91 SRC (0.50) SRCYES1FGRFYNLYN
SCHEMBL15613521 0.89 SRC (0.47) SRCYES1FGRFYNLYN
SCHEMBL16886163 0.88 SRC (0.46) SRCYES1FGRFYNLYN
SCHEMBL15613676 0.87 BTK (0.44) SRCYES1FGRFYNLYN
SCHEMBL15613749 0.86 NUDT14 (0.56) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL16886158 0.86 SRC (0.51) SRCYES1FGRFYNLYN
SCHEMBL15613567 0.85 KCNH2 (0.56) SRCYES1FGRFYNLYN
SCHEMBL15613671 0.85 BTK (0.51) SRCLYNABL1LCKPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK SRC 2/4885YES1 39/4885FGR 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback